Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research Snapshot

One-page overview of trials, participants, papers, and research networks.

Clinical Guidelines

Trial-anchored manuals and protocol guidance with competency mapping.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

AskBeta
Pricing

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.

Home/Research/Psilocybin/Microdosing

Psilocybin for Microdosing

61 papers and 7 clinical trials exploring psilocybin as a treatment for microdosing.

CompoundClassic Psychedelic

Psilocybin

Psilocybin is a naturally occurring tryptamine psychedelic that acts as a prodrug to psilocin, a potent 5-HT2A receptor agonist. It is the furthest advanced psychedelic in clinical development, with two positive Phase III trials in treatment-resistant depression and expanding regulated access in Australia, Germany, and US states.

Full Psilocybin profile
IndicationAround 300 million people worldwide are affected by a variety of mental health conditions that microdosing may address.

Microdosing

Microdosing involves the regular consumption of sub-hallucinogenic doses of psychedelics, primarily for cognitive enhancement and emotional wellbeing. Although popularised through anecdotal reports, rigorous scientific evidence on its effects is still limited, pointing to a critical need for further research in this emerging field.

Full Microdosing profile

Academic Research

61 papers
Open Accessmeta

Characterizing Resting-State Brain Dynamics with Frequency-Resolved EEG Microstates: Parallel Analyses of Psilocybin Microdosing and Acute Inhaled DMT

This brain imaging secondary analysis of two studies compared resting-state EEG microstate patterns during psilocybin microdosing and acute inhaled DMT, and found that frequency-specific analysis picked up changes that broadband analysis sometimes missed. Psilocybin microdosing had subtle effects, while DMT produced broader shifts in brain activity patterns.

Published
May 8, 2026
Journal
Biorxiv
Authors
Tarailis, P., Griskova-Bulanova, I.
Paywallindividual

Cognitive and Subjective Effects of Psilocybin Microdosing: Results from Two Double-Blind Placebo-Controlled Longitudinal Trials

This set of two randomised, double-blind, placebo-controlled trials (n=141) investigated the longitudinal effects of microdosing psilocybin truffles on cognition and well-being in semi-naturalistic settings. Contrary to anecdotal reports, the study finds no significant improvements in cognitive control, memory, social cognition, or subjective well-being compared with placebo.

Published
February 1, 2026
Journal
Neuropharmacology
Authors
Prochazkova, L., Marschall, J., Lippelt, D. P., Schon, N. R., Kuchař, M., Hommel, B.
Open Accessindividual

Comparing single- and repeat-dose psilocybin with active placebo for migraine prevention in an exploratory randomized controlled clinical trial

In an exploratory randomised, double‑blind trial in adults with frequent migraine, single or two‑dose psilocybin produced reductions in migraine frequency similar to an active diphenhydramine placebo and no serious adverse events were observed. Incomplete blinding and nonsignificant between‑group differences despite large effect sizes in psilocybin arms indicate the need for larger, better‑controlled trials with headache‑specialist input to separate drug and non‑drug effects.

Published
December 29, 2025
Journal
Headache
Authors
Schindler, E. A. D., Gottschalk, C. H., Pittman, B. P., D'Souza, D. C.
Open Accessindividual

Microdosing psychedelics and its effect on creativity: Lessons learned from three double-blind placebo controlled longitudinal trials

This combined analysis (n=175) of three double-blind placebo-controlled longitudinal experiments investigated the effects of microdosing psilocybin (0.74 -; 1.71mg) on creativity and found that it increased the originality of their ideas while generating novel applications for ordinary things (divergent thinking). However, it did not increase the number of novel ideas, or their ability to detect features that are common across multiple things (convergent thinking).

Published
November 2, 2025
Journal
Neuropsychopharmacology
Authors
Prochazkova, L., van Elk, M., Marschall, J., Rifkin, B. D., Fiacchino, D., Fejer, G., Hommel, B., Schoen, N.
Open Accessindividual

Health-related behavioral changes following the use of psychedelics in naturalistic settings

This cross-sectional study (n=2,510) of US adults with psychedelic experience found that participants retrospectively reported widespread improvements in health behaviours including reduced alcohol (66%) and tobacco (49%) use, better dietary habits (49%), and decreased impulsivity (48-72%), with microdosers and frequent users showing greater positive changes.

Published
August 1, 2025
Journal
Preventative Medicine Reports
Authors
Teixeira, P. J., Jain, R., Penn, A. D., Cole, S. P., Jain, S., Moller, A. C., Amaro, H., Raison, C.
Open Accessindividual

Acute effects of psilocybin on the dynamics of gaze fixations during visual aesthetic perception

This double-blind study (n=23) using eye-tracking found that high doses of psilocybin mushrooms (0.5-3g dried) caused more localised visual exploration of paintings and less entropic fixation patterns compared to low doses, while increasing subjective emotional intensity without affecting aesthetic ratings of the artworks.

Published
July 9, 2025
Journal
Scientific Reports
Authors
Muller, S., Cavanna, F., de la Fuente, L. A., Bruno, N., D'Amelio, T., Pallavicini, C., Tagliazucchi, E.

Clinical Trials

7 trials
Not yet recruitingPhase I

Psilocybin Microdosing on Cognition, Mood and Quality of Life

This Phase I, randomised, double-blind, parallel trial (n=20) will study the effects of intermittent psilocybin microdosing on mood, cognition, subjective well‑being and brain structure/function in healthy adults with no history of psychedelic use aged 21–40. The primary aim is basic science: to evaluate whether 30 days of intermittent microdosed psilocybin produces measurable changes on psychological, cognitive and neuroimaging outcomes compared with placebo, in the presumed absence of overt psychedelic experiences. Participants will be randomised to receive either 2 mg powdered psilocybin (from Psilocybe cubensis) in capsules or matching 0 mg placebo capsules three times weekly for four weeks, with weekly assessments and re‑assessment after 30 days of steady dosing; primary outcome measures are assessed from enrolment to end of treatment (8 weeks). Outcomes include task‑based fMRI (Complex Working Memory Span task), structural and diffusion imaging (including NODDI), neuropsychological batteries (NIH Toolbox, Switching Stroop, Flanker, Penn Conditional Exclusion, Face‑Name Associative Memory, 9‑hole pegboard), personality and symptom scales (NEO‑FFI, Beck Depression and Anxiety Inventories, Harvard Flourishing), and ecological momentary assessments via MindLamp. Key eligibility features are no prior psychedelic use, ability to consent, effective contraception for women of childbearing potential, and exclusion for current mood/psychotic disorders, substance use disorders, significant medical/neurological illness or MRI contraindications.

Started
April 1, 2026
Type
interventional
Blinding
double
Randomized
Yes
Registry ID
NCT07449351
CompletedPhase I

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of MLS101 in Healthy Participants

This randomised, quadruple-blind, placebo-controlled trial (n=24 planned; 16 actual reported) will evaluate the safety, tolerability, and pharmacokinetics of multiple doses of MLS101 (a low-dose psilocybin formulation) in healthy adult participants.

Started
November 8, 2024
Type
interventional
Blinding
quadruple
Randomized
Yes
Registry ID
NCT06643637
WithdrawnPhase NA

Optimizing Microdosing and Meditation (OMM)

Open-label, randomised feasibility trial (n=24) comparing psilocybin microdosing alone versus microdosing plus meditation in healthy adults; four supervised microdoses over two weeks.

Started
October 1, 2024
Type
interventional
Blinding
none
Randomized
Yes
Registry ID
NCT06560658
CompletedPhase I

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MLS101 in Healthy Participants

This Phase I interventional, randomized, quadruple-blind, placebo-controlled study (planned n=80; ACTUAL 24) will assess safety, tolerability and pharmacokinetics of low-dose psilocybin (MLS101) in healthy adults using SAD and MAD cohorts.

Started
March 1, 2024
Type
interventional
Blinding
quadruple
Randomized
Yes
Registry ID
NCT06326606
CompletedPhase II

Microdosing Psychedelics to Improve Mood

Randomized, triple-blind, placebo-controlled crossover Phase II study (n=50) testing weekly 2 mg oral psilocybin microdoses versus placebo in adults with major depressive disorder.

Started
April 4, 2022
Type
interventional
Blinding
triple
Randomized
Yes
Registry ID
NCT05259943
WithdrawnPhase I

Mood and Cognitive Effects of Psilocybin in Healthy Participants (MELO)

Double-blind, randomised, placebo-controlled, within-subject study (n=20) testing six low/microdoses of oral psilocybin (0, 1, 2, 5, 8, 10 mg) in healthy volunteers to identify doses that improve mood, cognition and sleep without hallucinogenic effects.

Started
April 1, 2022
Type
interventional
Blinding
quadruple
Randomized
Yes
Registry ID
NCT05252598

Explore further

Search all Psilocybin papers Search all Microdosing trials Full Psilocybin profile Full Microdosing profile